News >

Osimertinib Continues to Gain Momentum as Frontline Therapy in EGFR+ NSCLC

Ellie Leick
Published: Thursday, Sep 19, 2019

Arek Z. Dudek, MD, PhD

Arek Z. Dudek, MD, PhD

Findings from the FLAURA study indicate that frontline osimertinib (Tagrisso) is more effective than erlotinib (Tarceva) or gefitinib (Iressa), especially for patients with brain metastases, and does not create more aggressive disease in patients with EGFR-mutated non–small cell lung cancer (NSCLC), explained Arek Z. Dudek, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication